Research reporting standards for radioembolization of hepatic malignancies.
作者信息
Salem Riad, Lewandowski Robert J, Gates Vanessa L, Nutting Charles W, Murthy Ravi, Rose Steven C, Soulen Michael C, Geschwind Jean-Francois H, Kulik Laura, Kim Yun Hwan, Spreafico Carlo, Maccauro Marco, Bester Lourens, Brown Daniel B, Ryu Robert K W, Sze Daniel Y, Rilling William S, Sato Kent T, Sangro Bruno, Bilbao Jose Ignacio, Jakobs Tobias F, Ezziddin Samer, Kulkarni Suyash, Kulkarni Aniruddha, Liu David M, Valenti David, Hilgard Philip, Antoch Gerald, Muller Stefan P, Alsuhaibani Hamad, Mulcahy Mary F, Burrel Marta, Real Maria Isabel, Spies Stewart, Esmail Abdulredha A, Raoul Jean-Luc, Garin Etienne, Johnson Mathew S, Benson Al B, Sharma Ricky A, Wasan Harpreet, Lambert Bieke, Memon Khairuddin, Kennedy Andrew S, Riaz Ahsun
机构信息
Department of Radiology and Medical Oncology, Section of Interventional Radiology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
出版信息
J Vasc Interv Radiol. 2011 Mar;22(3):265-78. doi: 10.1016/j.jvir.2010.10.029.
Abstract
摘要
相似文献
1
Research reporting standards for radioembolization of hepatic malignancies.
J Vasc Interv Radiol. 2011 Mar;22(3):265-78. doi: 10.1016/j.jvir.2010.10.029.
2
Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.
J Vasc Interv Radiol. 2017 Jan;28(1):1-15. doi: 10.1016/j.jvir.2016.09.024. Epub 2016 Nov 9.
3
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria.
J Vasc Interv Radiol. 2016 Apr;27(4):457-73. doi: 10.1016/j.jvir.2015.12.752. Epub 2016 Feb 2.
4
Invited commentary.
J Vasc Interv Radiol. 2011 Oct;22(10):1362-3. doi: 10.1016/j.jvir.2011.07.013.
5
Ruptured Hepatocellular Carcinoma following Transarterial Radioembolization.
J Vasc Interv Radiol. 2018 Sep;29(9):1302-1305. doi: 10.1016/j.jvir.2018.04.017.
6
Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres.
J Vasc Interv Radiol. 2013 Nov;24(11):1743-5. doi: 10.1016/j.jvir.2013.07.011.
7
Yttrium-90 Radioembolization for Breast Cancer Liver Metastases.
J Vasc Interv Radiol. 2016 Sep;27(9):1316-1319. doi: 10.1016/j.jvir.2016.06.016.
8
Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
Hepatogastroenterology. 2014 Sep;61(134):1529-34.
9
Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Melanoma Res. 2014 Jun;24(3):244-51. doi: 10.1097/CMR.0000000000000051.
10
Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
J Vasc Interv Radiol. 2019 Mar;30(3):298-304.e2. doi: 10.1016/j.jvir.2018.09.020.
引用本文的文献
1
Comparison of Dosimetry Models and Dose Thresholds for Predicting Pathologic Response to Yttrium-90 Radioembolization with Glass Microspheres.
Cardiovasc Intervent Radiol. 2025 Aug 20. doi: 10.1007/s00270-025-04161-0.
2
Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.
Dig Dis Sci. 2025 Jun 26. doi: 10.1007/s10620-025-09139-z.
3
Musculoskeletal abscopal effect: a review of the important imaging findings and their clinical relevance.
Skeletal Radiol. 2025 May 15. doi: 10.1007/s00256-025-04944-z.
4
Health Outcomes and Resource Consumption Analysis of Radioembolization with Y90 Glass Microspheres (TARE-Y90) Versus Transarterial Chemoembolization with Irinotecan (DEBIRI) in Patients with Liver Metastases from Colorectal Cancer in Spain.
Diagnostics (Basel). 2025 Mar 21;15(7):796. doi: 10.3390/diagnostics15070796.
5
Insights into handling and delivery of Y-90 radioembolization therapies.
Front Nucl Med. 2023 Mar 21;3:1075782. doi: 10.3389/fnume.2023.1075782. eCollection 2023.
6
Predictive Value of [Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [Y]-TARE: A Single-Center Experience.
Diagnostics (Basel). 2023 Jul 20;13(14):2432. doi: 10.3390/diagnostics13142432.
7
Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review.
BMC Gastroenterol. 2023 May 24;23(1):181. doi: 10.1186/s12876-023-02793-5.
8
Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances.
J Clin Med. 2023 Jan 24;12(3):918. doi: 10.3390/jcm12030918.
9
Simplification of dosimetry in Y-radioembolization therapy by dual planar images.
BMC Cancer. 2022 Dec 8;22(1):1288. doi: 10.1186/s12885-022-10392-y.
10
Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score.
Cancers (Basel). 2022 Oct 29;14(21):5324. doi: 10.3390/cancers14215324.
本文引用的文献
1
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
J Hepatol. 2011 Apr;54(4):695-704. doi: 10.1016/j.jhep.2010.10.004. Epub 2010 Oct 23.
2
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Gastroenterology. 2011 Feb;140(2):497-507.e2. doi: 10.1053/j.gastro.2010.10.049. Epub 2010 Oct 30.
3
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):163-71. doi: 10.1016/j.ijrobp.2009.10.062. Epub 2010 Apr 24.
4
Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
Cancer J. 2010 Mar-Apr;16(2):163-75. doi: 10.1097/PPO.0b013e3181d7e8cf.
5
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
JAMA. 2010 Mar 17;303(11):1062-9. doi: 10.1001/jama.2010.262.
6
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
7
Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy.
J Nucl Med. 2010 Feb;51(2):301-10. doi: 10.2967/jnumed.109.069278. Epub 2010 Jan 15.
8
Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1441-8. doi: 10.1016/j.ijrobp.2009.07.006. Epub 2010 Jan 7.
9
Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors.
Cardiovasc Intervent Radiol. 2010 Jun;33(3):523-31. doi: 10.1007/s00270-009-9717-1. Epub 2009 Oct 20.
10
First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):453-61. doi: 10.1007/s00259-009-1279-6. Epub 2009 Oct 10.
Zotero 插件